** U.S.-listed shares of Australia's Telix Pharmaceuticals TLX.AX, TLX.O fall 7.8% to $17.35
** Late on Sunday, co said the US FDA declined to approve its marketing application for Pixclara, an imaging agent for glioma brain cancer
** TLX said FDA has requested additional clinical evidence to progress the application, stating that the application cannot be approved in its current form
** An imaging agent is a substance used in medical scans to enhance the visibility of internal body structures
** Co said it plans to request a hearing with the FDA to understand the decision and explore ways to supplement their application
** The rejection does not affect the company's financial forecasts for 2025, co said
** Including session move, stock up 8.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.